Nombre del producto:1-Bromo-2,4-dimethyl-3-nitrobenzene

IUPAC Name:1-bromo-2,4-dimethyl-3-nitrobenzene

CAS:39053-43-5
Fórmula molecular:C8H8BrNO2
Pureza:95%
Número de catálogo:CM193216
Peso molecular:230.06

Unidad de embalaje Stock disponible Precio($) Cantidad
CM193216-5g in stock Ȥœ
CM193216-10g in stock ƅşƩ
CM193216-25g in stock ǺƩş
CM193216-50g in stock şȋƩ
CM193216-100g in stock ƅƏȋƏ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :39053-43-5
Fórmula molecular:C8H8BrNO2
Punto de fusión:-
Código de sonrisas:O=[N+](C1=C(C)C(Br)=CC=C1C)[O-]
Densidad:
Número de catálogo:CM193216
Peso molecular:230.06
Punto de ebullición:
Nº Mdl:MFCD00092653
Almacenamiento:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Lunresertib Camonsertib
Repare Therapeutics announces Fast Track Designation granted by the FDA for Lunresertib in combination with Camonsertib for the treatment of platinum-resistant ovarian cancer. Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1) is a regulator of CDK1 phosphorylation, and PKMYT1 is identified as synthetic lethal with cyclin E1 (CCNE1) amplification.
Lunresertib (RP-6306) is a first-in-class PKMYT1 inhibitor to enter clinical trial. Lunresertib is studied alone and in combination with Camonsertib in patients with advanced solid tumors. Camonsertib (RP-3500) is a potent and selective ATR inhibitor, that helps Lunresertib activate CDK1 and promotes premature mitosis. The combination is previously granted Fast Track Designation for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer.

Related Products